New combo therapy aims to control advanced prostate cancer

NCT ID NCT06894511

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 26 times

Summary

This study is for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. It tests whether adding a radioactive drug (lutetium-177 vipivotide tetraxetan) to another hormone therapy is safe and works better than the radioactive drug alone. The goal is to control the cancer, not cure it, and participants will continue treatment as needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arizona Center for Cancer Care

    Gilbert, Arizona, 85297, United States

  • Cancer And Blood Spclsts of AZ

    Casa Grande, Arizona, 85122, United States

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Urology Cancer Center PC

    Omaha, Nebraska, 68130, United States

Conditions

Explore the condition pages connected to this study.